Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Authors:
- Daqing SunDSDaqing Sun
- Yosup RewYRYosup Rew
- Michael D. BartbergerMBMichael D. Bartberger
- Hilary P. BeckHBHilary P. Beck
- Jude CanonJCJude Canon
- Ada ChenACAda Chen
- David ChowDCDavid Chow
- Tiffany L. CorrellTCTiffany L. Correll
- Lisa D. JulianLJLisa D. Julian
- Frank KayserFKFrank Kayser
- 6 May 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (10) , 4053-4070
Abstract
Structural analysis of both the MDM2–p53 protein–protein interaction and several small molecules bound to MDM2 led to the design and synthesis of tetrasubstituted morpholinone 10, an MDM2 inhibitor with a biochemical IC50 of 1.0 μM. The cocrystal structure of 10 with MDM2 inspired two independent optimization strategies and resulted in the discovery of morpholinones 16 and 27 possessing distinct binding modes. Both analogues were potent MDM2 inhibitors in biochemical and cellular assays, and morpholinone 27 (IC50 = 0.10 μM) also displayed suitable PK profile for in vivo animal experiments. A pharmacodynamic (PD) experiment in mice implanted with human SJSA-1 tumors showed p21WAF1 mRNA induction (2.7-fold over vehicle) upon oral dosing of 27 at 300 mg/kg.Keywords
This publication has 31 references indexed in Scilit:
- The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets SeriousAngewandte Chemie International Edition, 2011
- 1,4‐Thienodiazepine‐2,5‐diones via MCR (I): Synthesis, Virtual Space and p53‐Mdm2 ActivityChemical Biology & Drug Design, 2010
- Potent and Orally Active Small-Molecule Inhibitors of the MDM2−p53 InteractionJournal of Medicinal Chemistry, 2009
- Reaching for high-hanging fruit in drug discovery at protein–protein interfacesNature, 2007
- Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 InteractionJournal of Medicinal Chemistry, 2006
- Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in CellsJournal of Medicinal Chemistry, 2005
- Small-molecule inhibitors of protein–protein interactions: progressing towards the dreamNature Reviews Drug Discovery, 2004
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993